Related Experiment Video

Updated: May 31, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Neuroendocrine cancer vaccines in clinical trials

Byram W Bridle1

  • 1Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8N 3Z5, Canada. bridleb@mcmaster.ca

Expert Review of Vaccines
|June 23, 2011
PubMed

Insights

This review examines recent neuroendocrine cancer vaccine trials, highlighting common challenges like weak immune responses. Future research should focus on overcoming these barriers for improved cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Neuroendocrine tumors (NETs) are a diverse group of rare cancers.
  • Cancer vaccines represent a promising therapeutic strategy for NETs.
  • Recent advancements in immunotherapy have spurred interest in vaccine development for NETs.

Purpose of the Study:

  • To review neuroendocrine cancer vaccines evaluated in human clinical trials over the past five years.
  • To clarify the definition of neuroendocrine tumors.
  • To identify common strategies, barriers, and future directions in neuroendocrine cancer vaccine research.

Main Methods:

  • Systematic review of clinical trials on neuroendocrine cancer vaccines.
  • Analysis of vaccine efficacy, safety, and immunogenicity.
  • Discussion of challenges in neuroendocrine tumor definition and vaccine development.

Main Results:

  • Several neuroendocrine cancer vaccines have been tested in clinical trials.
  • Common barriers include the rarity of NETs and the difficulty in eliciting robust tumor-specific immune responses.
  • Neuroblastoma and small-cell lung cancer vaccines show relatively higher prevalence in trials.

Conclusions:

  • Neuroendocrine cancer vaccines face significant challenges, particularly in generating potent immune responses.
  • Further research is needed to optimize vaccine design and overcome immunological hurdles for effective NET treatment.
  • Clarifying NET definitions and focusing on prevalent subtypes like neuroblastoma and SCLC are crucial for advancing vaccine development.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...